Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2001
08/28/2001CA2212458C Vascular intimal hyperplasia-inhibitory composition
08/28/2001CA2203443C Hepatitis c virus asialoglycoproteins
08/28/2001CA2173272C Stimulation of stem cells and other cells
08/28/2001CA2107552C Use of deprenyl to maintain, prevent loss, or recover nerve cell function
08/28/2001CA2101572C Benzoxazinones as inhibitors of hiv reverse transcriptase
08/28/2001CA2054738C 15-deoxyprostaglandin derivatives
08/28/2001CA2042113C Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
08/28/2001CA2041331C Nojirimycin derivatives
08/28/2001CA2017252C Retroviral protease inhibiting compounds
08/28/2001CA2015996C Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
08/25/2001CA2337565A1 Use of cladribine on a stent to prevent restenosis
08/24/2001CA2337588A1 Oxamides as impdh inhibitors
08/23/2001WO2001061039A2 5-hydroxytryptamine transporter gene polymorphisms
08/23/2001WO2001061017A2 Modified cytokines for use in cancer therapy
08/23/2001WO2001061009A2 Polypeptides and nucleic acids encoding same
08/23/2001WO2001061008A2 Polypeptides and nucleic acids encoding same
08/23/2001WO2001061000A1 5ht3 receptors of nematodes, polynucleotide molecules encoding same, and antagonists thereof
08/23/2001WO2001060983A2 Treatment for bone disorders
08/23/2001WO2001060975A2 Gene disruption methodologies in fungi for drug target discovery
08/23/2001WO2001060971A2 Method of controlling zoological and aquatic plant growth
08/23/2001WO2001060847A2 Avirulent, immunogenic flavivirus chimeras
08/23/2001WO2001060844A2 Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system
08/23/2001WO2001060837A2 Polypeptoid pulmonary surfactants
08/23/2001WO2001060835A1 Purine derivatives
08/23/2001WO2001060833A2 Motilide compounds
08/23/2001WO2001060832A2 Pluraflavins and derivatives thereof, process for their preparation and use thereof
08/23/2001WO2001060829A1 Phosphororganic compounds and the use thereof
08/23/2001WO2001060826A2 SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
08/23/2001WO2001060825A1 Pyrrolopyrimidinone derivatives, process of preparation and use
08/23/2001WO2001060824A1 Xanthine derivatives, intermediates and use for treating osteoporosis
08/23/2001WO2001060822A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
08/23/2001WO2001060821A1 Novel biarylcarboxamides
08/23/2001WO2001060816A1 Kinase inhibitors
08/23/2001WO2001060814A2 Pyrrole substituted 2-indolinone protein kinase inhibitors
08/23/2001WO2001060813A1 Beta-alanine derivatives and their use as receptor antagonists
08/23/2001WO2001060810A1 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
08/23/2001WO2001060808A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
08/23/2001WO2001060807A1 Aryloxyacetic acids for diabetes and lipid disorders
08/23/2001WO2001060806A2 Substituted arylpyrazines
08/23/2001WO2001060805A1 Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
08/23/2001WO2001060804A1 Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
08/23/2001WO2001060803A1 Fused imidazolium derivatives
08/23/2001WO2001060802A1 4-imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use as alpha-1a agonists
08/23/2001WO2001060798A1 Amine derivatives for the treatment of apoptosis
08/23/2001WO2001060796A1 PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID δ RECEPTOR AGONISTS
08/23/2001WO2001060786A1 Aminoalcohol derivatives
08/23/2001WO2001060784A1 Aniline-derived ligands for the thyroid receptor
08/23/2001WO2001060781A2 Diphenyl compounds, formulations and uses thereof
08/23/2001WO2001060778A2 Aspirin-triggered lipid mediators
08/23/2001WO2001060414A2 Genetic modification of the lung as a portal for gene delivery
08/23/2001WO2001060410A1 Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
08/23/2001WO2001060409A1 Improved paste formulations
08/23/2001WO2001060407A2 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
08/23/2001WO2001060400A2 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease
08/23/2001WO2001060399A1 Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase
08/23/2001WO2001060392A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1
08/23/2001WO2001060390A1 New toralactone and its derivation and the use of decreasing blood-fat and losing weight
08/23/2001WO2001060388A1 Cell activator
08/23/2001WO2001060387A1 Multiple drug resistance reversal agent
08/23/2001WO2001060386A1 Novel use of angelan from angelica gigas for treating diabetes mellitus
08/23/2001WO2001060385A1 Novel use of polysaccharide from phellinus linteus for treating diabetes mellitus
08/23/2001WO2001060382A1 Micelles
08/23/2001WO2001060381A1 Nucleoside analogs with carboxamidine-modified bicyclic base
08/23/2001WO2001060380A1 A parasiticidal formulation and a method of making this formulation
08/23/2001WO2001060379A1 Nucleoside analogs with carboxamidine modified monocyclic base
08/23/2001WO2001060378A2 Antiadhesive carbohydrates
08/23/2001WO2001060377A2 Methods for treatment of lysosomal storage diseases using biphosphonates
08/23/2001WO2001060376A1 Male contraceptive formulation comprising norethisterone
08/23/2001WO2001060375A2 Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration
08/23/2001WO2001060374A1 Use of paullone derivatives for making medicines
08/23/2001WO2001060372A2 Use of xanthine derivatives for preparing a medicine for preventing and treating osteoporosis
08/23/2001WO2001060371A1 Use of a compound for preparing a drug
08/23/2001WO2001060369A1 Inhibitors of prenyl-protein transferase
08/23/2001WO2001060367A1 Compositions comprising flavopiridol and their use for hiv therapy
08/23/2001WO2001060366A1 Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
08/23/2001WO2001060365A1 Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
08/23/2001WO2001060364A1 Method for reducing or eliminating smoking
08/23/2001WO2001060363A1 A method for synthesizing leflunomide
08/23/2001WO2001060362A1 TNF-α INHIBITORS
08/23/2001WO2001060361A1 Novel use of prodigiosin for treating diabetes mellitus
08/23/2001WO2001060359A1 Physiologic activity of a benzopyran derivative originating from propolis
08/23/2001WO2001060358A1 Method and compositions for treating fibrotic diseases
08/23/2001WO2001060357A1 New use
08/23/2001WO2001060356A1 Method for improving bone modeling and chondrocyte functioning in growing canines
08/23/2001WO2001060355A1 Modulation of bone formation
08/23/2001WO2001060354A1 Cancer remedy comprising anthranilic acid derivative as active ingredient
08/23/2001WO2001060353A1 Liquid preparation with improved absorbability
08/23/2001WO2001060352A1 Use of alpha 1a adrenoceptor agonists with alpha 1b and alpha 1d antagonism for the treatment of stress urinary incontinence
08/23/2001WO2001060351A2 Nitroacridine/tumor inhibitor compositions
08/23/2001WO2001060350A2 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
08/23/2001WO2001060349A2 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.
08/23/2001WO2001060348A2 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
08/23/2001WO2001060347A2 Method for treating ocular pain
08/23/2001WO2001060346A2 Nutritional formulation containing prebiotic substances
08/23/2001WO2001060345A2 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator
08/23/2001WO2001060344A2 Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections
08/23/2001WO2001060343A2 Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
08/23/2001WO2001060342A2 Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid for treating infectious diseases
08/23/2001WO2001060341A1 Powder formulation
08/23/2001WO2001060326A2 Cosmetic or pharmaceutical composition containing sesquiterpene lactone